BioSyent (RX.V) Akcija Kursas
BioSyent Kursas
Pajamos augo 19,3 % per metus per pastaruosius 19 metus iki 43,05 mln. CAD. Pelnas akcijai augo 18,6 % per metus per pastaruosius 19 metus. BioSyent grynoji marža dabar yra 20,9 %, sumažėjo nuo 21,9 % prieš kelerius metus. BioSyent šiuo metu siūlo apie 1,12 % dividendo pajamingumą. Išmokų koeficientas yra apie 25 % pelno. Dividendas augo 71,0 % per metus per pastaruosius 3 metus. Analitikų tikslinės kainos mediana yra 16,83 CAD, t. y. žemiau dabartinę kainą 6,0 %. Iš 7 analitikų 6 rekomenduoja pirkti — bendras konsensusas yra Pirkti.
BioSyent akcijos kaina
Gaukite šiuos duomenis per Eulerpool API
100 000 užklausų/mėn. nemokamai · be kortelės
BioSyent akcija ir akcijų analizė
Dažnai užduodami klausimai apie BioSyent akciją
The business model of Biosyent Inc is focused on acquiring or in-licensing pharmaceutical and healthcare products. The company identifies niche markets with unmet medical needs and seeks regulatory approval to provide branded pharmaceuticals or health products that address those needs. Biosyent Inc aims to improve patient outcomes by offering innovative and effective treatment options in areas such as cardiovascular health, dermatology, neurology, and pediatrics. By partnering with established companies or acquiring the rights to specific products, Biosyent Inc brings affordable and quality medicines to market, providing patients with improved access to vital healthcare solutions.
Biosyent Inc is primarily active in the pharmaceutical and healthcare industries.
The main competitors of Biosyent Inc in the market include pharmaceutical companies like Apotex Inc, Teva Pharmaceutical Industries Ltd, and Mylan N.V.
Biosyent Inc is a pharmaceutical company based in Canada. It was founded in 2004 and has since become a leader in the specialty pharmaceutical industry. The company focuses on acquiring or in-licensing niche pharmaceutical products, with a goal to provide reliable and effective therapeutic options to patients and healthcare professionals. Biosyent Inc has a successful track record of commercializing pharmaceutical products and has established a strong presence in the Canadian market. With a commitment to high-quality medications, Biosyent Inc continuously strives to meet the evolving healthcare needs of the population.
Biosyent Inc has achieved significant milestones since its inception. The company has successfully launched and commercialized multiple pharmaceutical and healthcare products in Canada. This includes obtaining regulatory approvals for important drugs, expanding their product portfolio, and establishing strategic partnerships with global pharmaceutical companies. Biosyent Inc has also demonstrated consistent revenue growth and increased market share, highlighting its strong performance in the industry. With their commitment to innovation and delivering high-quality products, Biosyent Inc continues to contribute to the advancement of healthcare and pharmaceuticals.
Biosyent Inc is primarily present in Canada and the United States.
Biosyent Inc is a pharmaceutical company that values innovation, sustainability, and customer-centricity. Their corporate philosophy revolves around providing high-quality, niche pharmaceutical products to meet the evolving healthcare needs of patients. With a focus on sourcing and licensing unique product opportunities, Biosyent Inc has built a strong reputation as a reliable partner within the healthcare industry. By utilizing their expertise in regulatory affairs and product commercialization, Biosyent Inc strives to improve patient outcomes while delivering value to their shareholders.
Analitikai šiuo metu nustato vidutinę BioSyent akcijos tikslinę kainą 16,83 CAD (mediana: 16,83 CAD), t. y. −6,0 % palyginti su paskutine kaina. Konsensusas pagrįstas 7 analitikų reitingais.
7 analitikai šiuo metu vertina BioSyent akciją: 6 rekomenduoja pirkti, 1 laikyti ir 0 parduoti. 2026 m. analitikai tikisi, kad BioSyent gaus 73,20 mln. CAD pajamų ir 1,05 CAD pelno akcijai.
Pagal dabartinį kursą BioSyent akcija kainuoja 11,29 EUR (17,90 CAD).
BioSyent akcija (RX.V) kotiruojama 2 biržose, įskaitant: Toronto (RX.V).
Biosyent Inc is a pharmaceutical company headquartered in Canada that focuses on the development, marketing, and distribution of innovative products. The company specializes in medications in the areas of dermatology, gastroenterology, urology, and pain management. The business strategy of Biosyent Inc is to bring new products to the market that are needed by the growing number of patients and healthcare providers. In addition, the company also produces generics, which it offers at lower costs than the originals. Biosyent Inc aims to improve the lives of patients through better healthcare solutions. The company is active in various regions and works with partners in Canada, the US, and Europe. Through targeted investments and marketing initiatives, Biosyent Inc has managed to expand its reach and diversify its offerings. The company collaborates closely with physicians, pharmacies, and customers to tailor its offerings to their needs. In the field of dermatology, the company offers preparations for acne, eczema, psoriasis, and other skin problems. In gastroenterology, Biosyent Inc has developed medications that can be used to treat gastrointestinal diseases such as inflammatory bowel disease, Crohn's disease, and ulcerative colitis. In urology, the company offers a solution for erectile dysfunction, and in pain management, it provides effective opioid antagonists in the form of nasal sprays and sublingual tablets. In addition to pharmaceutical products, Biosyent Inc also offers diagnostics and a solution for measuring urine flow. To further improve its products, the company also invests in researching new technologies and therapy forms. The company has a strong research and development department that works closely with the marketing and sales departments. Biosyent Inc strategically invests in the search for new active ingredients and solutions to continue offering its customers innovative products. Furthermore, the company works on optimizing its production processes and increasing its efficiency. The divisions of Biosyent Inc include: - Dermatology - Gastroenterology - Urology - Pain management Biosyent Inc. focuses on diversifying its offerings and producing innovative products that meet the needs of patients. Through the use of new technologies and procedures, the company aims to continue growing and strengthening its position in the market.
tikėtina pelnas BioSyent yra 73,20 mln. CAD. Šis skaičius grindžiamas dabartiniais finansiniais duomenimis ir atspindi įmonės verslo rezultatus.
tikėtina grynasis pelnas BioSyent yra 11,81 mln. CAD. Grynasis pelnas atspindi įmonės pelningumą po visų išlaidų atimties.
Kainų ir nuomos santykis (KGV) BioSyent šiuo metu yra 17,07. KGV lygina dabartinę akcijos kainą su pelnu už akciją ir padeda investuotojams įvertinti BioSyent akcijos vertę.
Kainų ir pardavimų santykis (KUV) BioSyent šiuo metu yra 2,75. KUV lygina rinkos kapitalizaciją su metinėmis pajamomis ir yra BioSyent akcijos įvertinimo metrika.
Eulerpool kokybės balas BioSyent yra 10/10.
BioSyent ISIN yra CA0906901081. ISIN (International Securities Identification Number) yra pasaulinė unikali vertybinių popierių identifikacijos sistema.
BioSyent WKN yra A1J6DY. WKN (Wertpapierkennnummer) yra šešiaženklė vokiška vertybinių popierių identifikacijos sistema.
BioSyent prekybos žymė yra RX.V. Ši biržos žymė naudojama BioSyent akcijoms prekiauti biržoje.
BioSyent akcija
BioSyent Pagrindiniai konkurentai
BioSyent Biržos simbolis
BioSyent FIGI
Visos BioSyent pagrindinės charakteristikos ir giluminė analizė
Mūsų akcijų analizė BioSyent akcijai apima svarbius finansinius rodiklius, tokius kaip apyvarta, pelnas, P/E santykis, P/S santykis, EBIT, taip pat informaciją apie dividendes. Be to, mes nagrinėjame aspektus, tokius kaip akcijos, rinkos kapitalizacija, skolos, nuosavas kapitalas ir įsipareigojimai BioSyent. Jei ieškote išsamesnės informacijos šiais klausimais, mūsų poskyriuose galite rasti išsamias analizes: